Pelosi plan to lower drug prices faces political challenges

House Speaker Nancy Pelosi’s (D-CA) bill to lower drug prices is facing new challenges as congressional Democrats debate changes to the plan, The Hill reported.

Centrist Democrats are warning leadership that if the plan moves further to the left, it could start to lose support and votes. Others are pushing for stronger reforms to “toughen up” the legislation.

“Pelosi will have to thread the needle between these dueling factions as she plans to bring the measure to the floor as soon as mid-November,” the report reads.

Pelosi introduced the plan in September, calling the bill The Lower Drug Costs Now Act. The plan enables the HHS to negotiate lower prices for hundreds of Medicare drugs––something currently prohibited under law.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.